Pseudomyxoma peritonei: Sudden cardiac death complicating postoperative intraperitoneal treatment with 5-fluorouracil

Digestive Surgery

Volumn 16, Issue 1, 1999, Pages 80-82

  El Attar, Ayman F ^a   Skeel, Roland T ^a   Howard, John M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

5 Fluorouracil toxicity; Adjuvant intraperitoneal therapy; Cardiotoxicity; Pseudomyxoma peritonei

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADULT; ARTICLE; AUTOPSY; BOLUS INJECTION; CARDIOTOXICITY; CASE REPORT; CONTINUOUS INFUSION; CORONARY ARTERY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PERITONEUM PSEUDOMYXOMA; SUDDEN DEATH;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEATH, SUDDEN, CARDIAC; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; MALE; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI;

EID: 0033040514     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018682     Document Type: Article

References (30)

1. Robben NC, Pippas AW, Moore JO: The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993;71:493-509.
2. Ensley JF, Patel B, Kloner R, Kish JA, Wynne J, Al-Sarraf M: The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989;7:101-109.
3. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G: Cardiac toxicity of 5-fluorouracil: A study on 1083 patients. Tumori 1982;68: 505-510.
4. Stevenson DL, Mikhailidis DP, Gillet DS: Cardiotoxicity of 5-fluorouracil. Lancet 1977;ii: 406-407.
5. Pottage A, Holt S, Ludgate S, Langlands AO: Fluorouracil cardiotoxicity. Br Med J 1978;i: 547.
6. Soukop M, McVie JG, Calman KC: Fluorouracil cardiotoxicity. Br Med J 1978;i:1422.
7. Vorobiof DA: Cardiotoxicity of 5-fluorouracil. A case report. S Afr Med J 1982;61:634-635.
8. Labianca R, Luporini G: 5-Fluorouracil cardiotoxicity: The risk of rechallenge (letter, comment). Ann Oncol 1991;2:383.
9. Anderson NR, Lokich JJ, Moore C: The syndrome of 5-fluorouracil cardiotoxicity: An elusive cardiopathy [letter]. Cancer 1993;72: 2287-2288.
10. Patel B, Kloner RA, Ensley J, Muhyi A, Kish J, Wynne J: Fluorouracil cardiotoxicity: Left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238-243.
11. McLachlan SA, Millward MJ, Toner GC, Guiney MJ, Bishop JF: The spectrum of 5-fluorouracil cardiotoxicity. Med J Aust 1994;161: 207-209.
12. Dent RG, McColl I: Letter: 5-Fluorouracil and angina (letter). Lancet 1975;i:347-348.
13. Collins C, Walden PL: Cardiotoxicity of 5-fluorouracil. Cancer Treatment Rep 1987;71: 733-736.
14. Hannaford RS: Sudden death associated with 5-fluorouracil administration (letter to the editor). Med J Aust 1992;157:425.
15. Millward MJ, Ganju V, Buck M: Cardiac arrest - a manifestation of 5-fluorouracil cardiotoxicity. Aust NZ Med 1988;18:693-695.
16. Vidal-Jove J, Steves MA, Banez-Sese GB, Litwin FP, Sugarbaker PH: Curative approach to pseudomyxoma peritonei. Contemp Surg 1991;38:13-20.
17. Sullivan MH, Sugarbaker PH: Treatment of pseudomyxoma peritonei in a geriatric population. J Surg Oncol 1995;58:121-124.
18. Sugarbaker PH, Kern K, Lack E: Malignant peudomyxoma peritonei of colonie origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum 1987; 30:772-779.
19. Nasr MF, Kemp GM, Given PT Jr: Pseudomyxoma peritonei: Treatment with intraperitoneal 5-fluorouracil. Eur J Gynecol Oncol 1993;3:213-217.
20. Gough DB, Donohue JH, Schutt AJ. Gonchoroff N, Goellner JR, Wilson TO, et al: Pseudomyxoma peritonei: Long term patient survival with an aggressive regional approach. Ann Surg 1994;219:112-119.
21. Sugarbaker PH: Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer (review). World J Surg 1995;19:235-240.
22. Fernandez RN, Daly JM: Pseudomyxoma peritonci. Arch Surg 1980;115:409-414.
23. Speyer JL, Collins JM, Dedrick RL, et al: Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980;49:567-572.
24. Sugarbaker PH, Zhu BW, Sese GB, et al: Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:323-329.
25. Markman M: Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies? Cancer Investigation 1995;13: 625-628.
26. Gaveau The, Banzet P, Marncffe H, Viars P: Cardiovascular disorders in the course of antimitotic infusions at high doses. 30 clinical observations. Anes Anal Rean 1969;26:311-327.
27. Kleiman NS, Lehane DE, Geyer CE, Pratt CM, Young YB: Prinzmetals angina during 5-fluorouracil chemotherapy. Am J Med. 1987;82: 566-568.
28. Pottage A, Holt S, Ludgate S, Langlands AO: Fluorouracil cardiotoxicity. Br Med J 1978;i: 547.
29. Rezkella S, Kloner RA, Ensley J, Al-Sarraf M, Revels S, Olivenstein A, Bhasin S, Kerpel-Fronious S, Turi ZG: Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study. J Clin Oncol 1989;7:509-514.
30. Antonelli D, Beker B, Brazilay J: Early cardiotoxicity of 5-fluorouracil. G Ital Cardiol 1981; 11:1758-1761.